Vienna, VA (PRWEB) June 22, 2013
On Tuesday, the American Medical Association voted to define obesity as a disease. The vote and its implications were described in an article entitled "AMA declares obesity a disease" by Melissa Healy and Anna Gorman that was published in the Los Angeles Times on June 18, 2013. According to the article, this vote means that the leading American association of physicians believes that the 90 million Americans - 78 million adults and 12 million children - have a medical conduction for which they should seek treatment. The vote means that doctors are obligated to notify their patients if they feel they are affected by obesity, and insurance plans will become more likely to cover weight loss programs, according to the same Los Angeles Times article.
This vote was only the latest recognition of the impact that obesity causes not just to people affected by it, but also to society as a whole by increasing health care costs. In May 2012, Duke University researchers released their findings after having examined the costs of obesity to the American health care system. They found that "Keeping obesity rates level could yield a savings of nearly $550 billion in medical expenditures over the next two decades" according to Dr. Eric Finkelstein, pHD, the study's lead author. Researchers also conducted a forecast and project that in 2030 up to 42 percent of the overall American population could be affected by obesity. The study and the information above are available in a summary entitled "Keeping Obesity Rates Level Could Save Nearly $550 Billion Over Two Decades" available at dukehealth.org that was published on May 7, 2012.
These studies show that the impact of obesity can affect both individuals and society as a whole by increasing medical expenses. However, these votes were not without controversy. According to a June 18, 2013 article from Medpage by David Pittman entitled "AMA House Votes Against Council, Calls Obesity a Disease," the AMA's Council on Science and Public Health had objected to the vote because they were concerned about people deciding not to focus on preventing it. This vote means that increasingly people will come to be counseled by their physicians about the serious impacts that obesity can have on their health.
To treat the growing problem of obesity, Shoppharmacycounter.com offers PhenObestin 37.5, a prescription-strength dietary supplement that is available without a prescription. PhenObestin's active ingredient is Phenylethylamine, and it is intended to relieve hunger and boost energy as part of a program to lose weight. It is an alternative having to endure the potential side effects of Phentermine or Adipex. Phentermine/Adipex side effects include depression, drowsiness, irritability, increased blood pressure levels, and nervousness. By contrast, PhenObestin includes all-natural ingredients from the cocoa and acacia blackbush plants that are processed in a laboratory based in Indianapolis that is compliant with cGMP-FDA standards.
PhenObestin 37.5 is available from shoppharmacycounter.com as part of a special summer sale. Purchase two bottles and you will save $132.60, while purchasing three bottles will result in a savings of $224. To find out more information or to place your order, visit shoppharmacycounter.com today.
Based in the suburbs of Maryland, ShopPharmacyCounter.com offers effective weight loss products while providing customers with a unique shopping experience. Their offerings strive to assist customers to lose weight as effortlessly as possible. With a commitment to quality and client satisfaction, ShopPharmacyCounter.com has helped countless individuals tackle weight related problems.
Operating as one-of-a-kind online pharmacy, their customers come from every corner of the world. Celebrating a proud legacy of a customer-base that continues to grow, ShopPharmacyCounter.com works towards ensuring health for every single client. Dealing in supplements, muscle building vitamins and a wide array of weight loss products, they never fail to meet and exceed expectations.